NO3090119T3 - - Google Patents

Info

Publication number
NO3090119T3
NO3090119T3 NO14823980A NO14823980A NO3090119T3 NO 3090119 T3 NO3090119 T3 NO 3090119T3 NO 14823980 A NO14823980 A NO 14823980A NO 14823980 A NO14823980 A NO 14823980A NO 3090119 T3 NO3090119 T3 NO 3090119T3
Authority
NO
Norway
Application number
NO14823980A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3090119(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3090119T3 publication Critical patent/NO3090119T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO14823980A 2013-03-14 2014-12-19 NO3090119T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
NO3090119T3 true NO3090119T3 (enExample) 2018-03-31

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14823980A NO3090119T3 (enExample) 2013-03-14 2014-12-19

Country Status (28)

Country Link
US (1) US20140274934A1 (enExample)
EP (4) EP3318258B1 (enExample)
JP (3) JP6563894B2 (enExample)
KR (2) KR101853605B1 (enExample)
CN (3) CN105007921B (enExample)
AU (3) AU2014239322B2 (enExample)
BR (1) BR112015020918A2 (enExample)
CA (1) CA2901818C (enExample)
CY (1) CY1121474T1 (enExample)
DK (1) DK2968302T3 (enExample)
EA (2) EA030482B1 (enExample)
ES (1) ES2654109T3 (enExample)
HK (1) HK1255257A1 (enExample)
HR (1) HRP20171898T1 (enExample)
HU (1) HUE036069T2 (enExample)
IL (2) IL240445B (enExample)
LT (1) LT2968302T (enExample)
MX (1) MX2015012536A (enExample)
NO (1) NO3090119T3 (enExample)
PL (1) PL2968302T3 (enExample)
PT (1) PT2968302T (enExample)
RS (1) RS56735B1 (enExample)
SG (2) SG11201507361YA (enExample)
SI (1) SI2968302T1 (enExample)
SM (1) SMT201800017T1 (enExample)
TW (2) TW202002979A (enExample)
WO (1) WO2014152635A1 (enExample)
ZA (1) ZA201705080B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EA030482B1 (ru) 2013-03-14 2018-08-31 Эббви Инк. Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX2016005393A (es) * 2013-10-25 2016-08-11 Abbvie Inc Metodos para tratar vhc.
WO2015095572A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
MX2016012722A (es) * 2014-04-02 2016-12-16 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN108778764B (zh) 2016-01-08 2020-09-04 恩图鲁斯特咨询卡有限公司 具有卡片返回路径的卡片印刷机构
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
MX394461B (es) * 2016-09-23 2025-03-24 Abbvie Inc Ajuste de la dosis.
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
WO2019200005A1 (en) * 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2293796A1 (en) * 2008-06-10 2011-03-16 Janssen Pharmaceutica, N.V. Telaprevir dosing regimen
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EA020031B1 (ru) * 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
HUE028384T2 (en) * 2010-09-21 2016-12-28 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
EA030482B1 (ru) 2013-03-14 2018-08-31 Эббви Инк. Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv

Also Published As

Publication number Publication date
EP3733180A1 (en) 2020-11-04
KR20180045055A (ko) 2018-05-03
EA201890507A1 (ru) 2018-07-31
IL267927A (en) 2019-09-26
EP2968302B9 (en) 2019-02-13
JP6563894B2 (ja) 2019-08-21
SG10201709840UA (en) 2018-01-30
ZA201705080B (en) 2019-02-27
PL2968302T4 (pl) 2018-04-30
US20140274934A1 (en) 2014-09-18
ES2654109T3 (es) 2018-02-12
MX2015012536A (es) 2016-01-12
JP2019214585A (ja) 2019-12-19
SMT201800017T1 (it) 2018-03-08
KR20150129035A (ko) 2015-11-18
BR112015020918A2 (pt) 2017-07-18
HK1255257A1 (en) 2019-08-09
CN108187056A (zh) 2018-06-22
EA201591701A1 (ru) 2016-02-29
LT2968302T (lt) 2017-12-27
CN105007921B (zh) 2018-12-11
EP2968302B1 (en) 2017-09-06
EP3318258B1 (en) 2020-05-13
PL2968302T3 (pl) 2018-04-30
AU2014239322B2 (en) 2018-04-05
CN109908353A (zh) 2019-06-21
CA2901818A1 (en) 2014-09-25
TW202002979A (zh) 2020-01-16
DK2968302T3 (en) 2017-12-18
AU2020201656A1 (en) 2020-03-26
JP2016513703A (ja) 2016-05-16
WO2014152635A1 (en) 2014-09-25
AU2014239322A1 (en) 2015-08-27
RS56735B1 (sr) 2018-03-30
WO2014152635A9 (en) 2014-12-11
AU2018202581B2 (en) 2019-12-05
JP2019167347A (ja) 2019-10-03
CY1121474T1 (el) 2020-05-29
HK1213191A1 (en) 2016-06-30
EA030482B1 (ru) 2018-08-31
AU2018202581A1 (en) 2018-05-10
EP3318258A1 (en) 2018-05-09
CA2901818C (en) 2021-05-04
SI2968302T1 (en) 2018-04-30
HUE036069T2 (hu) 2018-06-28
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
HRP20171898T1 (hr) 2018-04-06
EP2968302A1 (en) 2016-01-20
IL240445A0 (en) 2015-09-24
KR101853605B1 (ko) 2018-05-03
CN105007921A (zh) 2015-10-28
IL240445B (en) 2019-07-31
EP3915559A1 (en) 2021-12-01
TW201505633A (zh) 2015-02-16
SG11201507361YA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112015007533A2 (enExample)
BR112016011826A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014018502A2 (enExample)
BR112014017739A2 (enExample)
BR112014019326A2 (enExample)
BR112014018516A2 (enExample)
BR112014018480A2 (enExample)
BR112016000870A2 (enExample)
BR112014020341A2 (enExample)
BR112014017765A2 (enExample)
BR112014017669A2 (enExample)
BR112014021878A2 (enExample)
BR112016005529A2 (enExample)
BR112014019204A2 (enExample)
BR112014017901A2 (enExample)
BR112016010801A2 (enExample)
BR112014018207A2 (enExample)
BR112016009125A2 (enExample)
BR112014017722A2 (enExample)
BR112014017653A2 (enExample)
BR112016003282A2 (enExample)
BR112014017745A2 (enExample)